论文部分内容阅读
在骨髓移植患者合并的巨细胞病毒(CMV)肺炎,多因移植后的免疫功能不全而发病,其预后极为不良,作者用CMV-IG对CMV肺炎做了试验性预防。以5例白血病病人为对象,从市售静注用球蛋白中,将用荧光抗体(FA)法显示320倍的CMV抗体价者,作为CMV-IG,给予200mg/kg,1次/周,到移植后30～120天。CMV感染根据补体结合抗体(CF)价的上升和病毒分离来诊断,CMV肺炎则根据组织学所见与病毒分离来诊断。除1例外,其余4例在移植前CMV抗体阳性(CF抗体价8倍以上)。
CMV pneumonia combined with CMV-IG is an experimental prophylaxis in patients with CMV pneumonia, most of whom have a poor prognosis due to immune dysfunction after transplantation. Five patients with leukemia were treated with CMV-IG at a dose of 320 times the CMV antibody by a fluorescent antibody (FA) method from commercially available intravenous neutrophils to give 200 mg / kg once a week, After 30 to 120 days after transplantation. CMV infection is diagnosed on the basis of an increase in the value of complement-bound antibody (CF) and virus isolation, and CMV pneumonia is diagnosed on the basis of histological findings and virus isolation. Except for 1 case, the remaining 4 cases were positive for CMV antibody before transplantation (CF antibody price more than 8 times).